Activity and toxicity of gemcitabine and gemcitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients
- 1 March 2001
- journal article
- clinical trial
- Published by Elsevier in Lung Cancer
- Vol. 31 (2-3) , 277-284
- https://doi.org/10.1016/s0169-5002(00)00194-x
Abstract
No abstract availableKeywords
This publication has 13 references indexed in Scilit:
- Gemcitabine plus vinorelbine in advanced non-small cell lung cancer: a phase II study of three different dosesBritish Journal of Cancer, 2000
- Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment TrialsNew England Journal of Medicine, 1999
- Gemcitabine plus vinorelbine in nonsmall cell lung carcinoma patients age 70 years or older or patients who cannot receive cisplatinCancer, 1999
- Effects of Vinorelbine on Quality of Life and Survival of Elderly Patients With Advanced Non-Small-Cell Lung CancerJNCI Journal of the National Cancer Institute, 1999
- Relative survival in elderly cancer patients in EuropeEuropean Journal Of Cancer, 1998
- Vinorelbine is well tolerated and active in the treatment of elderly patients with advanced non-small cell lung cancer. A two-stage phase II studyEuropean Journal Of Cancer, 1997
- Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trialsBMJ, 1995
- The EORTC QLQ-LC13: a modular supplement to the EORTC core quality of life questionnaire (QLQ-C30) for use in lung cancer clinical trialsEuropean Journal Of Cancer, 1994
- The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in OncologyJNCI Journal of the National Cancer Institute, 1993
- Reporting results of cancer treatmentCancer, 1981